Cassava Sciences Inc vs iShares Semiconductor ETF — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while iShares Semiconductor ETF trades at $552.86. The key difference: iShares Semiconductor ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SOXX | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.64 | $655.01 |
52-Week Low | $0.87 | $241.68 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
SOXX, the iShares Semiconductor ETF, trades at $550.61, up 3.88% in the last session, with a bullish technical signal driven by moving averages. Recent news highlights sector volatility, including a 21% plunge in July due to headwinds like short-seller commentary and competitive pressures, though major cloud company growth supports AI spending optimism. The ETF's concentration in 30 semiconductor stocks contrasts with broader tech diversification options.
Outlook hinges on semiconductor demand from AI and data centers, with potential from U.S. policy support, but risks include tariff impacts, high valuation concerns, and sector rotation. Investors face trade-offs between SOXX's focused exposure and broader, lower-fee alternatives amid ongoing market efficiency and inflow trends.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →